ALPHAMAB ONCOLOGY revenue breakdown overview

ALPHAMAB ONCOLOGY revenue for the last year amounted to 240.68 M HKD, the most of which — 241.74 M HKD — came from its highest performing source at the moment, Biologics of Oncology, the year earlier bringing 194.02 M HKD. The greatest contribution to the revenue figure was made by China — last year it brought ALPHAMAB ONCOLOGY 241.74 M HKD, and the year before that — 194.02 M HKD.